Drug Trial Radar · NCT06928142
A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Last checked: Nov 20, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
83
Actual
Start
Apr 23, 2025
Primary completion
Mar 13, 2027
Study completion Jun 4, 2027
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
Conditions
- Sjogren Disease
Interventions
SibeprenlimabBiological
400 mg administered SC Q4 weeks
PlaceboOther
Administered SC Q4 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI) scoreTime frame: 28 weeks
Locations
63 sites in 8 countries. Site status is shown where the registry gives one.
Medvin Clinical Research - Riverside
Riverside, California
Medvin Clinical Research - Tujunga
Tujunga, California
Bay Area Arthritis and Osteoporosis
Brandon, Florida
Clinical Research of West Florida Inc
Clearwater, Florida
GNP Research - Florida
Cooper City, Florida
Vantage Clinical Trials - Tampa - ClinEdge - PPDS
Tampa, Florida
OrthoIllinois, LTD
Rockford, Illinois
Arnold Arthritis and Rheumatology
Skokie, Illinois
Ochsner Clinic Foundation
Baton Rouge, Louisiana
Albuquerque Center for Rheumatology
Albuquerque, New Mexico
Bradenton Research Center Inc
The Bronx, New York
DJL Clinical Research PLLC
Charlotte, North Carolina
STAT Research
Vandalia, Ohio
Allen Arthritis
Allen, Texas
Tekton Research, LLC
Austin, Texas
Advanced Rheumatology of Houston
Houston, Texas
Accurate Clinical Research - Houston
Houston, Texas
Accurate Clinical Management, LLC
Katy, Texas
R & H Clinical Research
Katy, Texas
DOM Centro de Reumatología
Buenos Aires, Argentina
Expertia S.A- Mautalén Salud e Investigación
Buenos Aires, Argentina
Maffei Centro Médico
Buenos Aires, Argentina
Aprillus Asistencia e Investigacion de Arcis Salud SRL
Buenos Aires, Argentina
Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
San Juan, Argentina
Consultorios Médicos Dr. Doreski - Fundacion Respirar - PPDS
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Instituto CER S.A.
Quilmes, Buenos Aires, Argentina
Instituto Médico de la Fundación Estudios Clínicos
Rosario, Santa Fe Province, Argentina
Clínica Mayo de U.M.C.B. S.R.L
San Miguel de Tucumán, Tucumán Province, Argentina
Centro de Investigaciones Médicas Tucumán - PPDS
San Miguel de Tucumán, Tucumán Province, Argentina
Medical Center Medconsult Pleven OOD
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment Sveti Georgi EAD-15 A Vassil Aprilov Boulevard
Plovdiv, Bulgaria
Medical Center Excelsior OOD - PPDS
Sofia, Bulgaria
Diagnostic- Consultative Center Convex EOOD
Sofia, Bulgaria
Medical Center- Nova Clinic
Varna, Bulgaria
Mvz Rheumatologie Und Autoimmunmedizin Hamburg Gmbh
Hamburg, Germany
Medicover München Ost MVZ
München, Germany
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Universitätsklinikum Köln
Cologne, North Rhine-Westphalia, Germany
Olympion General Clinic
Pátrai, Achaïa, Greece
Laiko General Hospital of Athens (Site 1)
Athens, Attica, Greece
Showing 40 of 63 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.